Beta-O2 Technologies ^{For Profit}

Beta-O2 Technologies Ltd. is a biomedical company, developing a proprietary implantable bioreactor, the ßAir, for the treatment of patients with type 1diabetes (T1D). ßAir was developed to address the main problems of the otherwise successful procedure in which islets of Langerhans (i.e. pancreatic endocrine cells) are transplanted in diabetic patients, such as the need for life-long immunosuppressive pharmacological treatment and deterioration of functionality the transplanted islets over time due to insufficient oxygen supply. It is a small medical device, which is implanted in a minimally invasive procedure. The islet-cell-containing device is planned to provide patients with freedom from insulin injections and repeated monitoring of glucose levels. This innovative device also reduces the risk for hypoglycemic episodes as well as diabetes complications. ßAir provides very effective protection from the host immune system, thus eliminating the need for immunosuppressive therapy and preventing what could otherwise be a fatal immune response of the patient to the transplanted cells.